Allorion Therapeutics presents TYK2 inhibitor ARTS-011 for the treatment of inflammatory disease May 13, 2022 No Comments
Discovery of GB-1101, selective oral HDAC6 inhibitor with potent antitumor activity in vivo May 9, 2022 No Comments
CRD-1600 demonstrates robust immune modulatory properties in vitro and in vivo May 4, 2022 No Comments
Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders May 2, 2022 No Comments
BBT-207, a fourth-generation EGFR TKI with activity against most common mutants May 2, 2022 No Comments
RSS